Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Is Being Restructured by A Reverse Merger

Uni-Pharma Part 2 April 28, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113155567

Uni-Pharma Part 1 April 27, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113119285


Conclusion: April 26, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113104999

Part 1 April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006


Part 2 April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694


Part 3 April 22, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321

Part 4 April 23, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113014648

Part 5 April 24, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113056841

Part 6 April 25, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113091753

All Roads Lead To Tapei,Taiwan Uni-Pharma Takeover of Radient Pharmaceuticals Underway you understand along with USA Partners.





In this section we will discuss our alternative hypothesis. That being, Uni-Pharma will merge into the Radient Shell. When formulating a hypothesis one must also analyze the opinions of others. It is easy to say that William of Global Cancer Dx and Terry Lin of Uni-Pharma are utilizing Dr-70 off patent even though they are under non-compete and confidentiality clauses that are legally binding two years after a termination. Easy to say but difficult to prove. In other words "They have talked the talk but didn't walk the walk" as they walked away you understand. We know from our last Section in the interview with Terry Lin CEO of Uni-Pharma, he doesn't want to be a distributor of Onko-Sure, he wants to own it. How can Uni-Pharma own the full rights of DR-70 and Onko-Sure? He can't steal it as one has suggested by using it off patent when he is still under an agreement with AMDL Diagnostics Inc. One must know how to read the language within an agreement..Below taken from the agreement.

"The Agreement shall continue until the earlier of expiration of the last patent issued to us for the Tests, when UNI terminates the agreement by discontinuing the offering of the Tests,"

This is how to interpret it. Without the comma and replaced with and...

The Agreement shall continue until the earlier of expiration of the last patent issued to us for the Tests and when Uni terminates the agreement by discontinuing the offering of the tests. The termination consists of two parts. Let us use logic form to demonstrate..

If: The patents expire
Then: Uni-Pharma discontinues the test.
Therefore: The agreement is terminated.

According to Gs, and the ads for the upcoming 2015 Bio Taiwan exhibit where Uni-Pharma is advertising we know that Uni-Pharma didn't stop offering the tests..Here it is in Logic form.

If: The patents expire
Then: Uni-Pharma continues offering the test.
Therefore: The patents expired and Uni-Pharma is still offering the tests and the agreement is still in force.



"The Agreement shall continue until the earlier of expiration of the last patent issued to us for the Tests, when UNI terminates the agreement by discontinuing the offering of the Tests,"


On June 6th 2013, we entered into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure®

The last patent expired on June 3, 2014. The agreement for the first year ended on June 6, 2014. Uni-Pharma paid royalties three days after the last patent expired. Uni-Pharma agreed to continue the agreement by paying royalties from June 6, 2014 and the upcoming June 6, 2015 royalty payment. We know this for a fact because they are advertising and still offering Onko-Sure in the 2015 Bio Taiwan exhibit. If the agreement was terminated on June 3, 2013 as some would suggest then the agreement would have had to end on June 3, 2013 and not June 6, 2013. The agreement is still in force.

1.3 {Licensing fees for each year shall be paid annually beginning in Calendar Year 2013, and become due June 6 each year of the duration of the agreement."


In the interview with Terry Lin he commented..Terry stated that Uni-Pharma added Onko-Sure to their product line. The distributorship was not announced until August 4, 2011.The agreement was expanded December 22, 2011.

http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-2457187542.html

http://contractservices.pharmaceutical-business-review.com/news/radient-expands-distribution-agreement-with-unipharma-221211

What is your strategy for further expansion?

TL: In 2010, thanks to Freia’s help, we added a cancer-detection device—an in-vitro diagnostics (IVD) product—to our portfolio. The device is extremely efficacious in monitoring the progress of colorectal cancer treatment. We spent two years learning the nuances of the IVD market, and hope to be listed in every major medical center in the country by next year. I believe our product can help at least 50 percent of the colorectal cancer patients in the country from 2014 onwards. But our plans do not stop at Taiwan!

We need a partner to help us manufacture the product, which is why we have formed an alliance with Pharmigene. This way, we will not need our own factory for production purposes.

FW: Most med tech companies in Taiwan are OEM manufacturers. We, on the other hand, will penetrate the market with a brand that we own the license to in this part of the world. We are looking to further develop an awareness of the brand’s name: Onko-Sure. Onko-Sure can help patients to monitor their condition, and it can even aid prevention.

The new partners, William GCDX in USA and Canada. etc..The Aussies in Australia, New Zealand.

"We will also need the right partners to help us along the way: at this time, we are not in a position to open our own international branches."

"However, we will respond to partner demand in countries like Turkey, Australia, and China when we bring Onko-Sure to those markets. We will reduce price, and give our distribution partners more space to be competitive and submit for reimbursement."

By 2018, Uni-Pharma will be present in more than ten countries, and the next generation of our product will be on the market.

FW: We are also planning an IPO. As you can imagine, developing our own product internationally will be a very capital-intensive endeavor.

TL: We anticipate an IPO around 2016. We hope to raise about NT$300 million.



Did someone say "No Mercy" That's absolutely correct.. No Mercy, only Uni-Pharma you understand..


On January 30, 2002 the Company granted Guangzhou A-Share Technology Co. Ltd., a People’s Republic of China corporation (“GAST”), the right to sell DR-70® kits in Taiwan and Hong Kong during the one year period ending January 31, 2003. GAST was formed by Jeanne Lai, a former voting trustee under the voting trust concerning 2,000,000 shares of our common stock held by Chinese Universal. Accordingly, GAST is considered a related party for financial reporting purposes. There are no minimum quantities or fixed payments required of either party to this agreement. During 2002, GAST purchased kits at a total cost of $24,750. An oral distribution arrangement for Taiwan and Hong Kong continues with Mercy Bio-Technology, Co., Ltd, a company related to GAST, based in Taiwan. During 2003, Mercy Bio-Technology purchased kits at a total cost of $12,350.

http://www.sec.gov/Archives/edgar/data/838879/000093639204000320/a97693e10ksb.htm

Also insolvency..No Bankruptcy...Why didn't the creeping takeover sell their 4.225 billion shares, and bought up to the last day of selling? Have Merger Time.."You Can't Touch This"

http://www.lexisnexis.com/legalnewsroom/corporate/b/blog/archive/2014/12/19/insolvent-company-directors-duties-to-creditors-under-delaware-law.aspx

Balance-sheet insolvency is when a person or company does not have enough assets to pay all of their debts. The person or company might enter bankruptcy, but not necessarily. Once a loss is accepted by all parties, negotiation is often able to resolve the situation without bankruptcy.

Mr. Lin has more two decades experiences in pharmaceutical industries. He is one of the co-founders and board membesr of Uni Pharma, which was established in 1998. Mr. Lin successfully leads Uni Pharma from distributing local pharmaceutical products to global products, and from pure distributor to gain in-house core-technology. Prior to Uni Pharma, he has worked in multinational pharmaceuticcal companies including Rhone Pouline Rorrer, Pfizer, and Bristol-Myers Squibb. Mr. Lin is also a certified pharmacist both in Taiwan and US.

http://pharmaboardroom.com/profiles/terry-lin/

We will continue with our Alternative Hypothesis "Uni-Pharma to reverse merge into the Radient Shell."